Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  13 results for ""Humans""

Your Filters

Publisher : health communications inc Subject : diabetes mellitus, type 2 Subject : glucose intolerance Geographic : united states Filter by : Subject
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Reduction in Diabetes-Related Hospitalizations and Medical Costs After Dexcom G6 Continuous Glucose Monitor Initiation in People with Type 2 Diabetes Using Intensive Insulin Therapy.

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/economics ; Hospitalization*/Hospitalization*/Hospitalization*/economics

  • Source: Advances in therapy [Adv Ther] 2024 Jun; Vol. 41 (6), pp. 2299-2306. Date of Electronic Publication: 2024 Apr 15.Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864

Record details

Read More Add to Saved list
×
Academic Journal

Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor.

  • Authors : Evans M; Diabetes Resource Centre, University Hospital Llandough, Penlan Road, Llandough, Cardiff, CF64 2XX, UK. .; Husain M

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use

  • Source: Advances in therapy [Adv Ther] 2024 May; Vol. 41 (5), pp. 1843-1859. Date of Electronic Publication: 2024 Feb 10.Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864

Record details

Read More Add to Saved list
×
Academic Journal

Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment.

  • Authors : Shubrook JH; Primary Care Department, Touro University California College of Osteopathic Medicine, Vallejo, CA, USA.; Radin M

Subjects: Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use

  • Source: Advances in therapy [Adv Ther] 2022 Sep; Vol. 39 (9), pp. 4114-4130. Date of Electronic Publication: 2022 Jul 07.Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864

Record details

Read More Add to Saved list
×
Academic Journal

Real-World Adherence to Antiretroviral Therapy Among HIV-1 Patients Across the United States.

  • Authors : McComsey GA; University Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH, USA.; Lingohr-Smith M

Subjects: Anti-HIV Agents*/Anti-HIV Agents*/Anti-HIV Agents*/therapeutic use ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy ; HIV Infections*/HIV Infections*/HIV Infections*/drug therapy

  • Source: Advances in therapy [Adv Ther] 2021 Sep; Vol. 38 (9), pp. 4961-4974. Date of Electronic Publication: 2021 Aug 14.Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864

Record details

Read More Add to Saved list
×
Academic Journal

Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States.

  • Authors : Blonde L; Department of Endocrinology, Ochsner Medical Center, New Orleans, LA, USA.; Patel C

Subjects: Canagliflozin*/Canagliflozin*/Canagliflozin*/therapeutic use ; Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/Diabetes Mellitus, Type 2*/drug therapy; Benzhydryl Compounds/Benzhydryl Compounds/Benzhydryl Compounds/therapeutic use

  • Source: Advances in therapy [Adv Ther] 2021 Jan; Vol. 38 (1), pp. 594-606. Date of Electronic Publication: 2020 Nov 12.Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864

Record details

Read More Add to Saved list
×
Academic Journal

Primary Care Physicians' Knowledge of the Cardiovascular Effects of Diabetes Medications: Findings from an Online Survey.

  • Authors : Shubrook JH; Touro University California, Vallejo, CA, USA. .; Pak J

Subjects: Health Knowledge, Attitudes, Practice*; Cardiovascular Diseases/Cardiovascular Diseases/Cardiovascular Diseases/*chemically induced ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy

  • Source: Advances in therapy [Adv Ther] 2020 Aug; Vol. 37 (8), pp. 3630-3639. Date of Electronic Publication: 2020 Jul 04.Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864

Record details

Read More Add to Saved list
×
Academic Journal

Evaluation of the Clinical and Economic Burden of Poor Glycemic Control Associated with Therapeutic Inertia in Patients with Type 2 Diabetes in the United States.

Subjects: Cost of Illness* ; Motivation*; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy

  • Source: Advances in therapy [Adv Ther] 2020 Feb; Vol. 37 (2), pp. 869-882. Date of Electronic Publication: 2020 Jan 10.Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864

Record details

Read More Add to Saved list
×
Academic Journal

Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States.

  • Authors : Hunt B; Ossian Health Economics and Communications, Basel, Switzerland. .; Hansen BB

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Glucagon-Like Peptides/Glucagon-Like Peptides/Glucagon-Like Peptides/*economics ; Glucagon-Like Peptides/Glucagon-Like Peptides/Glucagon-Like Peptides/*therapeutic use

  • Source: Advances in therapy [Adv Ther] 2019 Dec; Vol. 36 (12), pp. 3483-3493. Date of Electronic Publication: 2019 Oct 24.Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864

Record details

Read More Add to Saved list
×
Academic Journal

Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.

  • Authors : Nicolucci A; CORESEARCH, Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy. .; Candido R

Subjects: Cardiovascular Diseases/Cardiovascular Diseases/Cardiovascular Diseases/*chemically induced ; Cardiovascular Diseases/Cardiovascular Diseases/Cardiovascular Diseases/*prevention & control ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy

  • Source: Advances in therapy [Adv Ther] 2019 Oct; Vol. 36 (10), pp. 2895-2909. Date of Electronic Publication: 2019 Aug 13.Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864

Record details

Read More Add to Saved list
×
Academic Journal

Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review.

  • Authors : Okemah J; Western Washington Medical Group, Diabetes and Nutrition Education, Bothell, WA, USA. .; Peng J

Subjects: Early Diagnosis* ; Practice Guidelines as Topic*; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy

  • Source: Advances in therapy [Adv Ther] 2018 Nov; Vol. 35 (11), pp. 1735-1745. Date of Electronic Publication: 2018 Oct 29.Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864

Record details

Read More Add to Saved list
×
  • 1-10 of  13 results for ""Humans""